« POPE IV Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial 

By: Decomposed in POPE IV | Recommend this post (1)
Fri, 17 Feb 17 8:10 PM | 41 view(s)
Boardmark this board | POPES NEW and Improved Real Board
Msg. 20884 of 47202
Jump:
Jump to board:
Jump to msg. #

February 17, 2017

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

TheStreet.com
Adam Feuerstein
TheStreet.com

Celgene (CELG) took a step forward toward becoming a major player in the multiple sclerosis treatment market with the announcement Friday of positive results from a late-stage clinical trial of ozanimod. Celgene is conducting a second phase III study of ozanimid in multiple sclerosis patients, with results expected in the second quarter. The positive results from the first phase III study validate Celgene's decision to gain control of ozanimod through the acquisition of Receptos for $7 billion in 2015. Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug responsible for a majority of its revenue and profits.

http://finance.yahoo.com/m/d17775cb-d66a-3840-808c-410cafc307ba/ss_celgene-multiple-sclerosis.html




Avatar

Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months




» You can also:
« POPE IV Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next